Abstract
Neu-164 is a novel proprietary compound with anti-inflammatory and antioxidant properties. The potential anti-asthmatic activity of this compound was tested in a murine model for allergic asthma. Mice were sensitized with ovalbumin (Ova) i.p. on days 0 and 12 followed by 3 inhaled Ova challenges between days 22-26. Neu-164 was administered intratracheally at doses 5, 20 and 100 ug/kg on days 21-26. Dexamethasone (Dex) at a dose of 100 ug/kg and vehicle were used as positive and negative controls, respectively. On day 27 mice were evaluated for airway reactivity to methacholine using whole body plethysmography and 24 hours later mice were sacrificed for bronchoalveolar lavage (BAL) and serum sampling. Compared to vehicle control, Neu-164 at all 3 doses reduced methacholine-induced hyperresponsiveness. BAL cellular content showed a dose-dependent reduction in eosinophils numbers. In addition, the BAL fluid concentrations of IL-5, LTB-4 and total protein as well as serum IgE levels were reduced, at the higher doses of Neu-164. These data indicate at the potential anti-asthmatic properties of Neu-164 in reducing inflammatory and allergic markers and improving lung function.